Viroclinics Biosciences, a virology contract research organization (CRO), has acquired DDL Diagnostic Laboratory, a diagnostic solutions provider. The transaction enhances the combined group’s global position in anti-viral and vaccine testing and will serve to accelerate their growth strategy. 

Viroclinics was founded in 2001 and specializes in the fields of virology and global logistics services. DDL was founded in 1994 and is a laboratory in advanced (molecular) diagnostic testing. Both companies operate globally, serving biopharmaceutical companies active in the field of microbial vaccines and anti-virals. 

Viroclinics is a global leader in influenza and other viral targets, such as RSV and Polio, while DDL also specializes in the fields of Hepatitis and HPV. The combined organization will operate from four testing laboratories located in Europe and China, with access to a global network of processing facilities across 20 countries to coordinate sample collection in strategic regions worldwide to serve global trials.

“By joining with DDL, we will enhance Viroclinics’ leading position as a specialized CRO, adding to our service offering, capacity and geographic presence,” said Bob van Gemen, chief executive officer, Viroclinics Biosciences, who will serve as chief executive of the combined organization. “I look forward to working with the DDL team and continuing to build on our leading global position as a virology CRO.” 

Leen-Jan van Doorn, chief business officer and co-founder of DDL, said, “This is an exciting milestone for DDL. Our mission has been clear since the start of our company: to be a premier service provider in the global pharma services sector, with a focus on molecular diagnostics in infectious diseases.”